Current Appointments & Affiliations
Assistant Professor of Pediatrics
·
2021 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.
Journal Article Cancer Res Commun · March 1, 2025 ABSTRACT: The efficacy of chimeric antigen receptor T cells (CART) in solid tumors is limited by immune inhibition. In our study, we observed that effector cytokines mediated the upregulation of the PD-L1 immune checkpoint in primary glioblastoma. To offse ... Full text Link to item CiteAuthor Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Journal Article Nat Med · May 2024 Full text Link to item CiteUse, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.
Journal Article Neurooncol Pract · April 2024 BACKGROUND: Isocitrate dehydrogenase (IDH) is commonly mutated (mIDH) in gliomas, and this mutant enzyme produces the oncometabolite 2-hydroxyglutarate (2HG). 2HG promotes gliomagenesis and is implicated in epileptogenesis. Ivosidenib (IVO), a small molecu ... Full text Link to item CiteRecent Grants
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Clinical TrialPrincipal Investigator · Awarded by Research Institute at Nationwide Children's Hospital · 2024 - 2029Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2021 - 2027LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Thera
Clinical TrialPrincipal Investigator · Awarded by Day One Biopharmaceuticals · 2023 - 2027View All Grants
Education, Training & Certifications
University of Colorado, School of Medicine ·
2009
M.D.